Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02717507 · ClinicalTrials.gov registry record · Phase 2
Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors
A Phase 2 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 196
- Enrollment target
NCT02717507 is a Phase 2 study that has completed, run by Children's Oncology Group. The registered enrollment target is 196 participants.
The verdict
NCT02717507, a Phase 2 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 196 participants
- Enrollment target
Study Summary
This phase IIb trial studies how well low-dose carvedilol works in preventing heart failure in cancer survivors exposed to high dose anthracyclines for management of childhood cancer. Patients who received high-dose anthracycline chemotherapy are at a much greater risk for developing heart failure compared to survivors who didn't get any anthracycline chemotherapy. Heart failure happens when the heart muscle has been weakened and can't pump blood as well as it should. Carvedilol may help lower the risk of cardiovascular complications.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Carvedilol
- OTHER Placebo Administration
- OTHER Pharmacological Study
- OTHER Pharmacogenomic Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2016-04-04 |
| Est. Completion | 2025-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02717507
The ClinicalTrials.gov registry entry for NCT02717507 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 196 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02717507 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02717507 about?
NCT02717507 is a clinical study titled "Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors". This phase IIb trial studies how well low-dose carvedilol works in preventing heart failure in cancer survivors exposed to high dose anthracyclines for management of childhood cancer. Patients who received high-dose anthracycline chemotherapy are at a much greater risk for developing heart failure c...
What is the current status of trial NCT02717507?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 196 participants. The study started on 2016-04-04. Estimated completion is 2025-03-31.
What interventions are being tested in trial NCT02717507?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Carvedilol (DRUG), Placebo Administration (OTHER), Pharmacological Study (OTHER), Pharmacogenomic Study (OTHER).
Who is sponsoring clinical trial NCT02717507?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.